| __timestamp | BioMarin Pharmaceutical Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 179279000 |
| Thursday, January 1, 2015 | 152008000 | 186359000 |
| Friday, January 1, 2016 | 209620000 | 171785000 |
| Sunday, January 1, 2017 | 241786000 | 208136000 |
| Monday, January 1, 2018 | 315264000 | 198405000 |
| Tuesday, January 1, 2019 | 359466000 | 224169000 |
| Wednesday, January 1, 2020 | 524272000 | 245044000 |
| Friday, January 1, 2021 | 470515000 | 252314000 |
| Saturday, January 1, 2022 | 483669000 | 268225000 |
| Sunday, January 1, 2023 | 577065000 | 304629000 |
| Monday, January 1, 2024 | 580235000 | 324203000 |
In the competitive landscape of pharmaceuticals, cost efficiency is a critical factor for success. BioMarin Pharmaceutical Inc. and Taro Pharmaceutical Industries Ltd. have shown distinct trends in their cost of revenue from 2014 to 2023. BioMarin's cost of revenue has surged by approximately 345%, peaking in 2023, while Taro's costs have increased by about 70% over the same period. This stark contrast highlights BioMarin's aggressive growth strategy, potentially driven by increased production or expansion efforts. Meanwhile, Taro's more stable cost trajectory suggests a focus on maintaining operational efficiency. Notably, BioMarin's costs exceeded Taro's by nearly 90% in 2023, indicating a significant divergence in their financial strategies. As we look to 2024, Taro's data remains consistent, while BioMarin's figures are yet to be revealed, leaving room for speculation on future trends.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for AbbVie Inc. and BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Biogen Inc. and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and MorphoSys AG
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Ligand Pharmaceuticals Incorporated vs Taro Pharmaceutical Industries Ltd.